Literature DB >> 22158663

The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes.

Ian Ford1, Simon P Mooijaart, Suzanne Lloyd, Heather M Murray, Rudi G J Westendorp, Anton J M de Craen, Chris J Packard, Brendan Buckley, Catriona Barlow, David Preiss, Stuart M Cobbe, David J Stott, Naveed Sattar.   

Abstract

BACKGROUND: High serum alanine aminotransferase (ALT) levels have been associated with increased risk of diabetes and with increased mortality, but associations of variations of ALT in the normal range with outcomes have been less well studied.
METHODS: We studied the relationship between ALT, mortality and cardiovascular events in the West of Scotland Coronary Prevention Study (WOSCOPS) and the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trials that explicitly excluded subjects with clinically significant liver damage, plus the Leiden 85-plus, a study of survivors to age 85 years. The associations between ALT and morbidity and mortality outcomes were investigated using Cox proportional hazard models adjusting for a comprehensive panel of cardiovascular risk factors.
RESULTS: In all three study cohorts, ALT displayed an independent inverse relationship with all-cause mortality so that hazard ratios for fourth versus first quarter of ALT were all below 1.0; HRs 0.64 [95% confidence interval (CI) 0.50-0.81], 0.86 (0.73-1.01), 0.66 (0.50-0.87); WOSCOPS, PROSPER, Leiden 85-plus, respectively. In WOSCOPS and PROSPER, ALT was also inversely associated with risk of fatal plus non-fatal cardiovascular events, including coronary heart disease (CHD) events and stroke.
CONCLUSIONS: In three independent populations, ALT in the normal range displayed an inverse relationship with total mortality, cardiovascular events and non-cardiovascular events in middle-to-older aged subjects without evidence of clinically significant liver damage, independent of traditional cardiovascular and other risk factors. These findings indicate that the relationship between ALT and clinical outcomes is more complex than generally appreciated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22158663     DOI: 10.1093/ije/dyr172

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  19 in total

1.  Low Alanine Aminotransferase Levels in the Elderly Population: Frailty, Disability, Sarcopenia, and Reduced Survival.

Authors:  Umberto Vespasiani-Gentilucci; Antonio De Vincentis; Luigi Ferrucci; Stefania Bandinelli; Raffaele Antonelli Incalzi; Antonio Picardi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-06-14       Impact factor: 6.053

Review 2.  Effects of opium consumption on cardiometabolic diseases.

Authors:  Farzad Masoudkabir; Nizal Sarrafzadegan; Mark J Eisenberg
Journal:  Nat Rev Cardiol       Date:  2013-10-22       Impact factor: 32.419

3.  The association of low serum alanine aminotransferase activity with mortality in the US population.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Am J Epidemiol       Date:  2013-09-26       Impact factor: 4.897

4.  The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease.

Authors:  Mariana Lazo; Jonathan Rubin; Jeanne M Clark; Josef Coresh; Andrea L C Schneider; Chiadi Ndumele; Ron C Hoogeveen; Christie M Ballantyne; Elizabeth Selvin
Journal:  J Hepatol       Date:  2014-11-27       Impact factor: 25.083

5.  Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost.

Authors:  Wai Hoong Chang; Stefanie H Mueller; Sheng-Chia Chung; Graham R Foster; Alvina G Lai
Journal:  J Transl Med       Date:  2022-01-03       Impact factor: 5.531

6.  The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: the Insulin Resistance Atherosclerosis Study.

Authors:  C Lorenzo; A J Hanley; M J Rewers; S M Haffner
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

7.  Longitudinal Blood Pressure Control, Long-Term Mortality, and Predictive Utility of Serum Liver Enzymes and Bilirubin in Hypertensive Patients.

Authors:  Linsay McCallum; Jeemon Panniyammakal; Claire E Hastie; Jonathan Hewitt; Rajan Patel; Gregory C Jones; Scott Muir; Matthew Walters; Naveed Sattar; Anna F Dominiczak; Sandosh Padmanabhan
Journal:  Hypertension       Date:  2015-05-04       Impact factor: 10.190

8.  Predictive value of a profile of routine blood measurements on mortality in older persons in the general population: the Leiden 85-plus Study.

Authors:  Anne H van Houwelingen; Wendy P J den Elzen; Simon P Mooijaart; Margot Heijmans; Jeanet W Blom; Anton J M de Craen; Jacobijn Gussekloo
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

9.  Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial.

Authors:  Pedram Shokouh; Adel Joharimoghadam; Hamidreza Roohafza; Masoumeh Sadeghi; Allahyar Golabchi; Maryam Boshtam; Nizal Sarrafzadegan
Journal:  PPAR Res       Date:  2013-04-18       Impact factor: 4.964

10.  Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the UK Biobank.

Authors:  Ming-Ming He; Zhe Fang; Dong Hang; Feng Wang; Georgios Polychronidis; Liang Wang; Chun-Han Lo; Kai Wang; Rong Zhong; Markus D Knudsen; Scott G Smith; Rui-Hua Xu; Mingyang Song
Journal:  Int J Cancer       Date:  2020-11-02       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.